Recruiting at 32 sites Phase 2 Dementia, Alzheimer's Type

Dementia, Alzheimer's Type study: SAR448851

Official title A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

ClinicalTrials.gov ID: NCT07688213

What this study is testing

What is SAR448851?

an investigational oral capsule being studied as a potential treatment for early Alzheimer's disease

Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The study aims to see if SAR448851 is safe and can improve symptoms in early Alzheimer’s. It also compares the drug to a placebo.
Who it's for
Adults who have mild cognitive impairment due to Alzheimer’s or mild Alzheimer’s dementia and show brain amyloid signs.
What's involved
Participants take one oral dose of SAR448851 or a placebo each day, attend regular clinic visits for check‑ups and tests, and may join an open‑label extension or a higher‑dose group if eligible.
Time commitment
The trial lasts up to about 111 weeks (roughly two years), with treatment for up to 96 weeks and scheduled study visits throughout.
  • Phase 2: a mid-size study of how well it works
  • You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 55 to 85

You may be able to join if

  • Participant must be 55 to 85 years (inclusive) of age, at the time of signing the informed consent.
  • Diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) (National Institute on Aging-Alzheimer's Association [NIA-AA] Stage 3)...
  • Have a global Clinical Dementia Rating (CDR) score 0.5 to 1.0 and a CDR-Memory Box score ≥ 0.5 at screening.
  • Have a study partner who must provide separate written informed consent at screening.
  • The participant has evidence of cerebral amyloid pathology confirmed by positive visual read on amyloid positron emission tomography (PET) at...

You likely can't join if

  • The participant has any history of significant neurological disease including but not limited to, frontotemporal dementia, Lewy body dementia...
  • The participant has evidence of more than 4 microhemorrhages (\<10 mm in diameter) or superficial siderosis.
  • The participant carries two copies of the apolipoprotein-E epsilon 4 (APOE4) allele (APOE4/4).
  • The participant is currently receiving or has previously received any anti-amyloid immunotherapy (including, but not limited to, aducanumab...
  • The participant is currently receiving anticoagulant therapies.
  • The participant has had malignancy in the 3 years prior to Screening, excluding basal cell carcinoma, squamous cell carcinoma of the skin, melanoma...

The study team makes the final eligibility decision.

Where it is enrolling

  • Long Beach, California, United States
  • Oakland, California, United States
  • Naples, Florida, United States
  • Orlando, Florida, United States
  • Stuart, Florida, United States
  • Tampa, Florida, United States
  • The Villages, Florida, United States
  • Wellington, Florida, United States
  • Newton, Massachusetts, United States
  • Springfield, New Jersey, United States
  • Portland, Oregon, United States
  • Plymouth Meeting, Pennsylvania, United States
  • East Providence, Rhode Island, United States
  • Dallas, Texas, United States
  • Macquarie Park, New South Wales, Australia
  • Ivanhoe, Victoria, Australia
  • Melbourne, Victoria, Australia
  • Ottawa, Ontario, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada

+ 11 more site(s).

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 55 years to 85 years. The study team makes the final eligibility decision.

Where is this trial taking place?

This study is enrolling now at Long Beach, California, United States; Oakland, California, United States; Naples, Florida, United States; Orlando, Florida, United States; Stuart, Florida, United States; Tampa, Florida, United States and 25 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.